Phase 2Recruiting
Study of MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)
Phase 2b Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study of MAR001 in Patients With Elevated Triglycerides and Remnant Cholesterol (TYDAL-TIMI 78)
- Sponsor
- Marea Therapeutics (Industry)
- Enrollment
- 316 planned
- Conditions
- Hypertriglyceridemia
- Interventions
- MAR001; Placebo
- Ages
- adults, older adults
- Registry
- NCT07028749
Full record on ClinicalTrials.gov
From the registry
The primary objective of the study is to evaluate the effect of MAR001 compared to placebo on levels of TG in adults with elevated TG and RC.
Primary outcomes
- Primary Endpoint
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered
Papers citing this trial
- ANGPTL4 Inhibition in Adults with Elevated Triglyceride Levels
The New England journal of medicine